Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission
- PMID: 8988955
- DOI: 10.1176/ajp.154.1.31
Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission
Abstract
Objective: Demonstration of antidepressant efficacy beyond 6 months has infrequently been addressed, and no long-term efficacy data exist for patients with chronic atypical depression.
Method: Sixty patients with atypical depression (according to Columbia University criteria) of at least 2 years' duration and who had improved with imipramine or phenelzine were stabilized for 6 months and then randomly continued the same medication or placebo for 6 months.
Results: Several baseline differences suggested that patients who entered the discontinuation trial on a regimen of phenelzine were more chronically depressed than the imipramine-treated patients. Survival analysis showed a marked advantage for phenelzine relative to placebo. In addition, patients switched to placebo from phenelzine experienced a recurrence of depressive symptoms significantly more often than patients switched to placebo from imipramine. Patients maintained with imipramine did not have lower relapse rates than those switched from imipramine to placebo. Recurrence rates were 23% for patients maintained on a regimen of phenelzine, 41% for those maintained on a regimen of imipramine, 47% for those switched from imipramine to placebo, and 87% for placebo-treated patients originally treated with phenelzine.
Conclusions: Patients with chronic atypical depression are at high risk of recurrence if phenelzine is withdrawn 6 months after initial improvement. Similar findings were not demonstrated for imipramine; this replicates acute trials demonstrating imipramine's relative ineffectiveness in patients with atypical depression. Differences in recurrence rates after the switch to placebo from phenelzine and imipramine could be due to the two drugs' different mechanisms of action or to baseline differences in the two populations.
Similar articles
-
Efficacy in long-term treatment of depression.J Clin Psychiatry. 1996;57 Suppl 2:24-30. J Clin Psychiatry. 1996. PMID: 8626360 Review.
-
A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives.Int J Eat Disord. 1994 Jan;15(1):1-9. doi: 10.1002/1098-108x(199401)15:1<1::aid-eat2260150102>3.0.co;2-e. Int J Eat Disord. 1994. PMID: 8124322 Clinical Trial.
-
Chronic depression: response to placebo, imipramine, and phenelzine.J Clin Psychopharmacol. 1993 Dec;13(6):391-6. J Clin Psychopharmacol. 1993. PMID: 8120152 Clinical Trial.
-
Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.Psychopharmacol Bull. 1989;25(4):524-34. Psychopharmacol Bull. 1989. PMID: 2698483 Review.
-
Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.Arch Gen Psychiatry. 1989 Dec;46(12):1080-7. doi: 10.1001/archpsyc.1989.01810120022005. Arch Gen Psychiatry. 1989. PMID: 2686575 Clinical Trial.
Cited by
-
An assessment of the reporting of tapering methods in antidepressant discontinuation trials using the TIDieR checklist.Int J Clin Pharm. 2023 Oct;45(5):1074-1087. doi: 10.1007/s11096-023-01602-z. Epub 2023 Jun 3. Int J Clin Pharm. 2023. PMID: 37269440 Free PMC article.
-
Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013495. doi: 10.1002/14651858.CD013495.pub2. Cochrane Database Syst Rev. 2021. PMID: 33886130 Free PMC article.
-
Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis.Mol Psychiatry. 2021 Jan;26(1):118-133. doi: 10.1038/s41380-020-0843-0. Epub 2020 Jul 23. Mol Psychiatry. 2021. PMID: 32704061 Free PMC article.
-
Early response in cognitive-behavior therapy for syndromes of medically unexplained symptoms.BMC Psychiatry. 2017 May 25;17(1):195. doi: 10.1186/s12888-017-1351-x. BMC Psychiatry. 2017. PMID: 28545580 Free PMC article.
-
Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials.Int J Neuropsychopharmacol. 2015 Jul 7;19(2):pyv076. doi: 10.1093/ijnp/pyv076. Int J Neuropsychopharmacol. 2015. PMID: 26152228 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical